multiple myeloma: adcs and bites
Published 3 years ago • 161 plays • Length 3:06Download video MP4
Download video MP3
Similar videos
-
1:29
the future of adcs in treating multiple myeloma
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
0:36
the potential of immunotherapies in the myeloma treatment landscape
-
2:33
the role of bispecific antibodies in the treatment of patients with multiple myeloma
-
12:26
treating ultra high risk myeloma patients in a unique uk study | martin kaiser, md | ash 2021
-
5:54
redirectt-1 results: teclistamab talquetamab in r/r multiple myeloma
-
7:24
covid-19: outcomes in multiple myeloma
-
1:59
myeloma: bites & cars
-
0:59
defining the origins of multiple myeloma
-
2:57
novel targeted therapies for the treatment of bpdcn
-
1:45
the advent of bispecific antibodies for multiple myeloma
-
2:44
novel bcma-targeting therapies to treat tce relapsed/refractory multiple myeloma
-
1:53
the future of multiple myeloma treatment
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
2:48
novel targets in multiple myeloma
-
2:46
managing patients with high-risk myeloma
-
1:11
advances that have been made in the molecular characterization of multiple myeloma
-
2:25
pre-clinical activity of ucartcs1 in multiple myeloma
-
2:44
myeloma qol through induction and maintenance
-
1:01
car-t: myeloma toxicities
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma